🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06911203
Recruiting Phase 2

A Study of BGM0504 in Participants With Obesity

NCT06911203 · tracked via the Priya Life Science China tracker
Sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Phase
Phase 2
Started
2025-04-03
Last updated
2025-10-28

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

BGM0504Tirzepatide

BGM0504: Administered SC

Tirzepatide: Administered SC

Study summary

To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * ● Able and willing to provide a written informed consent. * Male or female subjects, 18-65 years of age at the time of signing informed consent. * At screening visit, 35.0 ﹤BMI﹤ 45.0 kg/m2; * Diet and exercise control for at least 3 months before screening visit, and be of stable weight (± 5%) self-reported change within the last 3 months. Exclusion Criteria: * ●History of chronic or acute pancreatitis. * History of severe drug allergy or specific allergic disease or severe allergies. * Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2(MEN-2). * History of malignant tumors \[except carcinoma in situ with no recurrence within 5 years (except for malignant melanoma in situ), skin basal cell carcinoma and squamous cell carcinoma\]. * Suspected or confirmed history of alcohol or drug abuse; * Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), human immunodeficiency virus (HIV) or treponema pallidum (TP). * Donation or loss of 400 mL or more of blood within 3 months prior to screening, or blood donation during screening or within 3 months after the end of the trial. * Pregnant or lactating woman. * Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University People's Hospital Beijing Beijing Municipality Recruiting

On this site

📄 Mounjaro (tirzepatide) drug profile →

More BrightGene Bio-Medical Technology Co., Ltd. trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06911203 on ClinicalTrials.gov ↗ ← All trials in China